Loss of heterozygosity at 3p in benign lesions preceding invasive breast cancer

Journal of Surgical Research

Volumn 83, Issue 1, 1999, Pages 13-18

  Euhus, David M ^a,b   Maitra, Anirban ^a   Wistuba, Ignacio I ^a   Alberts, Arland ^a,b   Albores Saavedra, Jorge ^a   Gazdar, Adi F ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

3p; Benign breast lesions; Breast cancer; Loss of heterozygosity; Polymerase chain reaction

Indexed keywords

ALLELE; BENIGN TUMOR; BREAST BIOPSY; BREAST CANCER; CANCER INVASION; CASE REPORT; CHEMOPROPHYLAXIS; CHROMOSOME 3P; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; FIBROADENOMA; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0033134187     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsre.1998.5549     Document Type: Conference Paper

References (25)

1. Schlotterer C. Genomic evolution: Are microsatellites really simple sequences. Curr. Biol. 8:1998;R132.
2. Wistuba I. I., Lam S., Behrens C., Vermani A. K., Fong K. M., LeRiche J., Samet J. M., Srivastava S., Minna J. D., Gazdar A. F. Molecular damage in the bronchial epithelium of current and former smokers. J. Natl. Cancer Inst. 89:1997;1366.
3. Yin Y., Tainsky M. A., Bischoff F. Z., Strong L. C., Wahl G. M. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell. 70:1992;937.
4. Kastan M. B., Zhan Q., El-Deiry W. S., Carrier F., Jacks T., Walsh W. V. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell. 71:1992;587.
5. Kuerbitz S. J., Plunkett B. S., Walsh W. V., Kastan M. B. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA. 89:1992;7491.
6. Tseng S.-L., Yu J.-C., Yue C.-T., Chang S.-F., Chang T.-M., Wu C.-W., Shen C.-Y. Allelic loss of BRCA1, BRCA2, and adjacent loci in relation to TP53 abnormality in breast cancer. Genes Chromosomes Cancer. 20:1997;377.
7. Eyfjord J. E., Thorlacius S., Steinarsdottir M., Valgardsdottir R., Ogmundsdottir H. M., Anamthawat-Jonsson K. p53 abnormalities and genomic instability in primary human breast carcinoma. Cancer Res. 55:1995;646.
8. Sharan S. K., Morimatsu M., Albrecht U., Lim D. S., Regal E., Dinh C. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature. 386:1997;804.
9. Bergthorsson J. T., Johannsdottir J., Jonasdottir A., Eiriksdottir G., Egilsson V. Chromosome imbalance at the 3p14 region in human breast tumors: High frequency in patients with inherited predisposition due to BRCA2. Eur. J. Cancer. 34:1998;142.
10. Eiriksdottir G., Barkardottir R. B., Agnarsson B. A., Johannesdottir G., Olafsdottir K. High incidence of loss of heterozygosity at chromosome 17p13 in breast tumors from BRCA2 mutation carriers. Oncogene. 16:1998;21.
11. Tedeschi B., Vernole P., Sanna M. L., Nicoletti B. Population cytogenetics of aphidicholin-induced fragile sites. Hum. Genet. 89:1992;543.
12. Paradee W., Mullins C., He Z. Precise localization of aphidicolin-induced breakpoints on the short arm of human chromosome 3. Genomics. 27:1995;543.
13. Chen L. C., Matsumura K., Deng G., Kurisu W., Ljung B. M., Lerman M. I., Waldman F. M., Smith H. S. Deletion of two separate regions on chromosome 3p in breast cancers. Cancer Res. 54:1994;3021.
14. Sato T., Tanigami A., Yamakawa K. Allelotype of breast cancer: Cumulative allele losses promote tumor progression in breast cancer. Cancer Res. 50:1990;7184.
15. Devilee P., van den Broek M., Kuipers-Djkshoorn N., Kolluri R., Khan P. M. At least four different chromosomal regions are involved in loss of heterozygosity in human breast carcinoma. Genomics. 5:1989;554.
16. Ahmadian M., Wistuba I. I., Fong K. M., Behrens C., Kodagoda D. R., Saboorian M. H., Shay J., Tomlinson G. E., Blum J., Minna J. D., Gazdar A. Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands. Cancer Res. 57:1997;3664.
17. Dietrich C. U., Pandis N., Teixeira M. R., Bardi G., Gerdes A.-M. Chromosome abnormalities in benign hyperproliferative disorders of epithelial and stromal breast tissue. Int. J. Cancer. 60:1995;49.
18. Wistuba, I. Behrens, C. Milchgrub, S. Syed, S. Ahmadian, M. Virmoni, A. K. Kurvari, V. Cunningham, T. H. Ashfaq, R. Minna, J. D. Gazdar, A. F. Comparison of features in human breast cancer cell lines and their corresponding tumors, Int. J. Cancer.
19. Wistuba I. I., Behrens C., Milchgrub S., Virmani A. K., Jagirdar J., Thomas B., Ioachim H. L., Litzky L. A., Brambilla E. M., Minna J. D., Gazdar A. F. Comparison of molecular changes in lung cancers in HIV-positive and HIV-indeterminant subjects. J. Am. Med. Assoc. 279:1998;1554.
20. Hung J., Kishimoto Y., Sugio K. Allele-specific chromosome 3p deletions occur at an early stage in the pathogenesis of lung carcinoma. J. Am. Med. Assoc. 273:1995;558.
21. Panagopoulous I., Pandis N., Thelin S., Petersson C., Mertens F., Borg A., Kristofferson U., Mitelman F., Aman P. The FHIT and PTPRG genes are deleted in benign proliferative breast disease associated with familial breast cancer and cytogenetic rearrangements of chromosome band 3p14. Cancer Res. 56:1996;4871.
22. Deng G., Lu Y., Zlotnikov G., Thor A. D., Smith H. Loss of heterozygosity in normal tissue adjacent to breast cancers. Science. 274:1996;2057.
23. Dupont W. D., Parl F. F., Hartman W. H., Brinton L. A., Winfield A. C., Worrell J. A., Schuyler P. A., Plummer W. D. Breast Cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer. 71:1993;1258.
24. Dupont W. D., Page D. L. Breast Cancer risk associated with proliferative disease, age at first birth and a family history of breast cancer. Am. J. Epidemiol. 125:1987;769.
25. Dupont W. D., Page D. L. Risk factors for breast cancer in women with proliferative breast disease. N. Engl. J. Med. 312:1985;146.